Cite This Page

Jump to: navigation, search

Bibliographic details for Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test

Citation styles for Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test

APA style

Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test. (2024, January 28). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 08:20, May 5, 2024 from https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129.

MLA style

"Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 28 Jan 2024, 03:59 UTC. 5 May 2024, 08:20 <https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 28 January 2024, 03:59 UTC, <https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129> [accessed 5 May 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129 (accessed May 5, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 28, 03:59 UTC [cited 2024 May 5]. Available from: https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129.

Bluebook style

Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test, https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129 (last visited May 5, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129",
   note = "[Online; accessed 5-May-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred: 

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Everolimus in addition bevacizumab is an efficient firstline answer to patients using sophisticated papillary alternative renal mobile carcinoma Results from the phase II test --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Everolimus_in_addition_bevacizumab_is_an_efficient_firstline_answer_to_patients_using_sophisticated_papillary_alternative_renal_mobile_carcinoma_Results_from_the_phase_II_test&oldid=621129}",
   note = "[Online; accessed 5-May-2024]"
 }


Retrieved from "https://news.npo.digital/index.php?title=Special:CiteThisPage"